{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T05:58:27Z","timestamp":1775455107574,"version":"3.50.1"},"reference-count":41,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The 20th European AIDS Conference (EACS) was held in Paris, France, over 4\u2009days in October 2025. The event was co\u2010chaired by Milosz Parczewski (Poland), Karine Lacombe, Bruno Spire and Jean\u2010Michel Molina (France). This meeting provided up\u2010to\u2010date information on HIV prevention, treatment and cure research, as well as comorbidities.<\/jats:p>","DOI":"10.1111\/hiv.70195","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:37:09Z","timestamp":1770903429000},"page":"628-634","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Highlights from the 20th European AIDS Conference: 15\u201318 October 2025, Paris, France"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-4891","authenticated-orcid":false,"given":"Tristan J.","family":"Barber","sequence":"first","affiliation":[{"name":"Department of HIV Medicine Royal Free London NHS Foundation Trust  London UK"},{"name":"Institute for Global Health, University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Akinosoglou","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Patras  Patras Greece"},{"name":"Department of Internal Medicine and Infectious Diseases University General Hospital of Patras  Patras Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 I.","family":"Bernardino","sequence":"additional","affiliation":[{"name":"HIV Unit, Internal Medicine Department Hospital La Paz, IdiPAZ  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9718-5811","authenticated-orcid":false,"given":"Uwe","family":"Koppe","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease Epidemiology Robert Koch Institute  Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelia Georgia","family":"Kostaki","sequence":"additional","affiliation":[{"name":"Department of Hygiene, Epidemiology and Medical Statistics, Medical School National and Kapodistrian University of Athens  Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Libois","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Saint Pierre University Hospital, Universit\u00e9 Libre de Bruxelles  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-0703","authenticated-orcid":false,"given":"Maria","family":"Mazzitelli","sequence":"additional","affiliation":[{"name":"Department of Safety and Bioethics \u2013 Infectious Diseases Section Universit\u00e0 Cattolica del Sacro Cuore  Rome Italy"},{"name":"Department of Medical and Surgical Sciences Fondazione Policlinico Universitario Agostino Gemelli IRCCS  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Skrzat\u2010Klapaczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Adults' Infectious Diseases Hospital for Infectious Diseases, Medical University of Warsaw  Warsaw Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9811-1213","authenticated-orcid":false,"given":"Christina K.","family":"Psomas","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases European Hospital Marseille  Marseille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"EACS Young Investigator Network (YING)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf415"},{"key":"e_1_2_11_3_1","unstructured":"BritesC FigueroaM CecchiniD et al.Subgroup analysis of dolutegravir\/lamivudine\u2010in ART\u2010na\u00efve adults living with HIV with CD4 counts below 200 cells\/mL: results from the DOLCE study. Paper presented at: 20th European AIDS Conference; 2025; Paris; Poster eP134."},{"key":"e_1_2_11_4_1","unstructured":"De LagardeM De MiguelR BlancoJL et al.Evolution of proviral DNA M184V\/I over 96\u2009weeks does not predict virologic failure of dolutegravir\/lamivudine in the VOLVER trial. Paper presented at: 20th European AIDS Conference; 2025; Paris; MeP10.4."},{"key":"e_1_2_11_5_1","unstructured":"ColsonAE CrofootGE RuanePJ et al.Oral weekly islatravir plus lenacapavir in virologically suppressed people with HIV\u20101: 96 week outcomes from a phase 2 study. Paper presented at: 20th European AIDS Conference; 2025; Paris; PS15.5.LB."},{"key":"e_1_2_11_6_1","unstructured":"EronJ ColsonAE RamgopalMN et al.Patient\u2010reported outcomes from people with HIV\u20101 receiving once\u2010weekly oral islatravir in combination with lenacapavir: phase 2 week 48 results. Paper presented at: 20th European AIDS Conference; 2025; Paris; eP133."},{"key":"e_1_2_11_7_1","unstructured":"OgbuaguO McMahonJ GaurA et al.Efficacy and safety of a twice\u2010yearly regimen of lenacapavir teropavimab and zinlirvimab: phase 2 week 52 results. Paper presented at: 20th European AIDS Conference; 2025; Paris; PS09.2."},{"key":"e_1_2_11_8_1","unstructured":"GrieselR D'AgostinoR DonattiC et al.Safety and tolerability of N6LS administered intravenously or subcutaneously: promising results from part 1 of the EMBRACE study. Paper presented at: 20th European AIDS Conference; 2025; Paris; PS09.1."},{"key":"e_1_2_11_9_1","unstructured":"HillA Perez NavarroA ManaluS et al.Comparable efficacy but increased adverse events and treatment\u2010emergent resistance with injectable cabotegravir\/rilpivirine compared to standard oral antiretroviral therapy: two systematic reviews and meta\u2010analyses. Paper presented at: 20th European AIDS Conference; 2025; Paris; MeP21.2."},{"key":"e_1_2_11_10_1","unstructured":"DeschanvresC HocquelouxL Cabi\u00e9A et al.Virological failure on long\u2010acting cabotegravir + rilpivirine: associated factors and remaining options in the real\u2010world DAT'AIDS cohort. Paper presented at: 20th European AIDS Conference; 2025; Paris; eP124."},{"key":"e_1_2_11_11_1","unstructured":"BolesJ ElliotE FoxD et al.Cabotegravir injections are more acceptable than lenacapavir injections following a single dose: results from CLARITY a randomized crossover study of long\u2010acting injectable antiretrovirals. Paper presented at: 20th European AIDS Conference; 2025; Paris; MeP20.4.LB."},{"key":"e_1_2_11_12_1","unstructured":"MasiaM DomingoP CurranA et al.Virological non\u2010inferiority and lower weight gain with DTG\/3TC versus BIC\/FTC\/TAF: 96\u2010week final results from the PASO\u2010DOBLE (GeSIDA 11720) randomised multicentre open label non\u2010inferiority trial. Paper presented at: 20th European AIDS Conference; 2025; Paris; abstract RO3.8.LB."},{"key":"e_1_2_11_13_1","unstructured":"OrkinC BisshopFR GatanagaH et al.Weight and body composition after switch to doravirine\/Islatravir (100 mg\/0.25 mg) once daily from BIC\/FTC\/TAF in adults living with HIV\u20101: week 48 results from a randomized double\u2010blind phase 3 study. Paper presented at: 20th European AIDS Conference; 2025; Paris; PS01.2."},{"issue":"4","key":"e_1_2_11_14_1","first-page":"1515","article-title":"Review of HIV and breastfeeding guidelines across Europe: insights from the WAVE survey \u2018same, same, but different: European guidelines on HIV and breastfeeding","volume":"20","author":"Haberl L","year":"2025","journal-title":"HIV Med"},{"issue":"4","key":"e_1_2_11_15_1","article-title":"Breastfeeding and HIV in high\u2010income settings: exploring women living with HIV and health\u2010care providers' perspectives in Belgium","volume":"26","author":"Masquelier H","year":"2025","journal-title":"HIV Med"},{"issue":"4","key":"e_1_2_11_16_1","article-title":"Semi\u2010structured interviews with women living with HIV and their health\u2010care professionals to determine factors influencing counseling on infant feeding options: a qualitative study","volume":"26","author":"Van Der Wekken\u2010Pas L","year":"2025","journal-title":"HIV Med"},{"issue":"4","key":"e_1_2_11_17_1","article-title":"Would infant lamivudine prophylaxis during breastfeeding be an option to prevent vertical transmission of HIV?","volume":"26","author":"Gay L","year":"2025","journal-title":"HIV Med"},{"issue":"4","key":"e_1_2_11_18_1","article-title":"Advancing HIV care in pregnancy: trends in virological suppression, mother\u2010to\u2010child transmission, and postpartum retention over two decades","volume":"26","author":"Casari F","year":"2025","journal-title":"HIV Med"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00239-5"},{"issue":"4","key":"e_1_2_11_20_1","article-title":"Models of care for women living with HIV in Europe: a scoping review","volume":"26","author":"EACS WAVE Group","year":"2025","journal-title":"HIV Med"},{"issue":"4","key":"e_1_2_11_21_1","article-title":"Women living with HIV in Australia: development of a clinical monitoring tool","volume":"26","author":"Burdon R","year":"2025","journal-title":"HIV Med"},{"issue":"4","key":"e_1_2_11_22_1","article-title":"A retrospective review of referrals to specialist HIV\u2010led and gynaecology\u2010led menopause clinics","volume":"26","author":"Forbes K","year":"2025","journal-title":"HIV Med"},{"key":"e_1_2_11_23_1","unstructured":"NooriT.\u201cFive years left!\u201d What targets are in reach in Europe and which will we struggle to make? Session C1. Epidemiology\/public health\/models of care plenary lecture. Paper presented at: 20th European AIDS Conference; 2025; Paris."},{"key":"e_1_2_11_24_1","unstructured":"GilleeceY.Prevention of HIV PrEP options for women. Paper presented at: WAVE Workshop: Making WAVES: Women HIV & the Power of Research. 20th European AIDS Conference; 2025; Paris."},{"key":"e_1_2_11_25_1","unstructured":"Calder\u00f3n\u2010CifuentesPA.Educational needs assessment: PrEP in transcommunities. Paper presented at: WAVE Workshop: Making WAVES: Women HIV & the Power of Research. 20th European AIDS Conference; 2025; Paris."},{"key":"e_1_2_11_26_1","unstructured":"SandulescuO.The why and the how of addressing PrEP equity across Europe. Paper presented at: Session: PS02 \u2010 scaling up PrEP to meet the needs of everyone. 20th European AIDS Conference; 2025; Paris."},{"key":"e_1_2_11_27_1","unstructured":"Duran RamirezJJ BotA JahaB et al.Trends and timing of HIV diagnoses among migrants: a 15\u2010year analysis from the Swiss HIV cohort study. Abstract PS15.1. Paper presented at: 20th European AIDS Conference; 2025; Paris."},{"key":"e_1_2_11_28_1","unstructured":"Fern\u00e0ndez\u2010L\u00f3pezL GogishviliM VicenteM et al.Strengthening community\u2010based integrated HIV\/STI\/VH prevention testing and linkage\u2010to\u2010care: first\u2010year outcomes of the CORE project. Session: PS02 \u2010 Scaling up PrEP to meet the needs of everyone. Paper presented at: 20th European AIDS Conference; 2025; Paris."},{"key":"e_1_2_11_29_1","unstructured":"DjureticT.Understanding the numbers: BBV prevalence data and monitoring. SPS8 \u2010 EuroTest special session: blood borne virus testing in emergency departments across Europe. Paper presented at: 20th European AIDS Conference; 2025; Paris."},{"key":"e_1_2_11_30_1","unstructured":"SPS8 \u2010 EuroTest special session: blood borne virus testing in emergency departments across Europe. Paper presented at: 20th European AIDS Conference; 2025; Paris."},{"key":"e_1_2_11_31_1","unstructured":"PaucardL BaltesV Lascoux CombeC et al.Bacterial STIs incidence among MSM with HIV in France: the ANRS PRIMO cohort. Paper presented at: 20thEuropean AIDS Conference; 2025; Paris; abstract PS11.1."},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101214"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70120"},{"key":"e_1_2_11_34_1","unstructured":"WimmersbergerD ZeebM BrunschweilerF et al.Doxycycline postexposure prophylaxis and the 4\u2010component meningococcal B vaccine among persons living with HIV at high risk for bacterial sexually transmitted infections in Switzerland. Paper presented at: 20th European AIDS Conference; 2025; Paris; abstract PS 15.2."},{"key":"e_1_2_11_35_1","unstructured":"MolinaJ\u2010M AssoumouL Didine KabaA et al.Doxycycline prophylaxis to prevent bacterial STIs: results of the open\u2010label extension phase of the ANRS 174 DOXYVAC trial. Paper presented at: 20th European AIDS Conference; 2025; Paris; abstract RO2.8.LB."},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00236-6"},{"key":"e_1_2_11_37_1","unstructured":"BruzzesiE DispiaceriS BagaglioS et al.Safety of a ChAdOx1.tHIVconsvX prime \u2010 MVA.tHIVconsvX boost vaccination regimen in people with HIV treated in primary infection: a phase I\/II randomized placebo\u2010controlled trial (HIV\u2010CORE 007). Paper presented at: 20th European AIDS Conference; 2025; Paris; abstract MeP17.3."},{"key":"e_1_2_11_38_1","unstructured":"LeeY BoniferR ChenZ et al.T\u2010cell modulation following therapeutic vaccination in people living with HIV (PLWH). Paper presented at: 20th European AIDS Conference; 2025; Paris; abstract O1.1."},{"key":"e_1_2_11_39_1","unstructured":"LimD FuO LiuX et al.Safety and analytical treatment interruption outcomes in a clinical trial of 2 broadly neutralizing antibodies plus vesatolimod in early\u2010treated South African women with clade C HIV\u20101. Paper presented at: 20th European AIDS Conference; 2025; Paris; abstract PS07.1."},{"key":"e_1_2_11_40_1","unstructured":"FauaC BernacchiS MoogC et al.Lenacapavir directs specific immunoproteasome\u2010mediated degradation of Gag proteins and increases the killing of HIV\u2010infected cells. Paper presented at: 20th European AIDS Conference; 2025; Paris; abstract PS07.2."},{"key":"e_1_2_11_41_1","unstructured":"GhosnJ ZenuniA MinierM et al.Systematic molecular screening for mpox in anal\/pharyngeal swabs in high\u2010risk MSM on PrEP: a substudy of the ANRS\u2010DOXYVAC trial. Paper presented at: 20th European AIDS Conference; 2025; Paris; abstract R01.5."},{"key":"e_1_2_11_42_1","unstructured":"PimentelV GiovanettiM SebastiaoCS et al.Impact of continental spread of HIV\u20101 integrase resistance on progress toward the WHO's 2030 elimination goals. Paper presented at: 20th European AIDS Conference; 2025; Paris; abstract MeP18.4."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70195","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70195","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T05:09:50Z","timestamp":1775452190000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/hiv.70195"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70195","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"2025-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}